SCHEMBL5536288

SCHEMBL5536288

CC(=O)Nc1cccc(C(F)(F)F)c1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
HPGD P15428 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
CYP1A2 P05177 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
POLB P06746 4/20 0.43
TAS2R14 Q9NYV8 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HTT P42858 1/20 0.42
TRPV1 Q8NER1 1/20 0.41
MAOA P21397 1/20 0.41
TSHR P16473 1/20 0.41
LMNA P02545 1/20 0.41
TIPARP Q7Z3E1 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1395802 0.84 POLB (0.58) ALDH1A1HPGDCYP1A2MEN1KMT2A
SCHEMBL30136232 0.84 POLB (0.58) ALDH1A1HPGDCYP1A2MEN1KMT2A
SCHEMBL2090320 0.83 POLB (0.46) ALDH1A1HPGDCYP1A2MEN1KMT2A
SCHEMBL12144664 0.83 EPHX2 (0.57) ALDH1A1HPGDRXFP1CYP1A2MEN1
SCHEMBL985910 0.83 TAS2R14 (0.57) ALDH1A1HPGDRXFP1CYP1A2MEN1
Chloromethane SCHEMBL10795405 0.82 POLB (0.56) ALDH1A1HPGDCYP1A2MEN1KMT2A
SCHEMBL30977689 0.81 HDAC1 (0.47) ALDH1A1HPGDRXFP1CYP1A2MEN1
SCHEMBL19638054 0.81 HDAC1 (0.47) ALDH1A1HPGDRXFP1CYP1A2MEN1
SCHEMBL9572107 0.80 RXFP1 (0.44) ALDH1A1HPGDRXFP1CYP1A2MEN1
SCHEMBL5537133 0.79 POLB (0.49) ALDH1A1HPGDCYP1A2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885HPGD 3159/4885RXFP1 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.